VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to announce its Q3 2026 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $0.14 million for the quarter. Parties may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. On average, analysts expect VistaGen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Performance

Shares of VTGN stock opened at $0.56 on Tuesday. VistaGen Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $5.14. The stock’s fifty day moving average is $1.44 and its two-hundred day moving average is $2.87. The firm has a market capitalization of $22.13 million, a P/E ratio of -0.29 and a beta of 0.33.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTGN. Two Sigma Investments LP increased its holdings in shares of VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after acquiring an additional 199,958 shares during the last quarter. Jane Street Group LLC acquired a new position in VistaGen Therapeutics in the second quarter valued at approximately $190,000. Geode Capital Management LLC increased its stake in VistaGen Therapeutics by 18.3% in the fourth quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock valued at $234,000 after purchasing an additional 54,556 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in VistaGen Therapeutics during the third quarter worth approximately $152,000. Finally, Marshall Wace LLP purchased a new stake in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $69,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on VTGN. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a research report on Wednesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, VistaGen Therapeutics presently has an average rating of “Reduce” and a consensus price target of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.